A Johnson & Johnson pharmaceutical unit focused on the development of hepatitis C research said it will end its program amid a crowded market. Janssen Sciences Ireland cited the increasing availability of a number of highly effective therapies addressing the medical need. Getty Images Shares of biotech company Achillion Pharmaceuticals were more than 20 percent lower Monday in premarket trading after it announced its hepatitis C collaboration with a Johnson & Johnson pharmace